Wikipedia

Efflux pump

(Redirected from Drug efflux)

An efflux pump is an active transporter in cells that moves out unwanted material. Efflux pumps are an important component in bacteria in their ability to remove antibiotics.[1] The efflux could also be the movement of heavy metals, organic pollutants, plant-produced compounds, quorum sensing signals, bacterial metabolites and neurotransmitters. All microorganisms, with a few exceptions, have highly conserved DNA sequences in their genome that encode efflux pumps. Efflux pumps actively move substances out of a microorganism, in a process known as active efflux, which is a vital part of xenobiotic metabolism. This active efflux mechanism is responsible for various types of resistance to bacterial pathogens within bacterial species - the most concerning being antibiotic resistance because microorganisms can have adapted efflux pumps to divert toxins out of the cytoplasm and into extracellular media.[2]

Protein TolC, the outer membrane component of a tripartite efflux pump in Escherichia coli.
AcrB, the other component of pump, Escherichia coli.

Efflux systems function via an energy-dependent mechanism (active transport) to pump out unwanted toxic substances through specific efflux pumps. Some efflux systems are drug-specific, whereas others may accommodate multiple drugs with small multidrug resistance (SMR) transporters.[3][4]

Efflux pumps are proteinaceous transporters localized in the cytoplasmic membrane of all kinds of cells. They are active transporters, meaning that they require a source of chemical energy to perform their function. Some are primary active transporters utilizing adenosine triphosphate hydrolysis as a source of energy, whereas others are secondary active transporters (uniporters, symporters, or antiporters) in which transport is coupled to an electrochemical potential difference created by pumping hydrogen or sodium ions into the cell.

Bacterial

edit

Bacterial efflux pumps are classified into five major superfamilies, based on their amino acid sequence and the energy source used to export their substrates:

  1. The major facilitator superfamily (MFS)[5]
  2. The ABC transporters[5]
  3. The small multidrug resistance family (SMR)[5]
  4. The resistance-nodulation-cell division superfamily (RND)[5]
  5. The multi antimicrobial extrusion protein family (MATE).[5]

Of these, only the ABC superfamily are primary transporters, the rest being secondary transporters utilizing proton or sodium gradient as a source of energy. Whereas MFS dominates in Gram positive bacteria, the RND family was once thought to be unique to Gram negative bacteria. They have since been found in all major kingdoms.[6]

Structure

edit

Efflux pumps generally consist of an outer membrane efflux protein, a middle periplasmic protein, an inner membrane protein, and a transmembrane duct. The transmembrane duct is located in the outer membrane of the cell. The duct is also bound to two other proteins: a periplasmic membrane protein and an integral membrane transporter. The periplasmic membrane protein and the inner membrane protein of the system are coupled to control the opening and closing of the duct (channel). When a toxin binds to this inner membrane protein, the inner membrane proteins gives rise to a biochemical cascade that transmits signals to the periplasmic membrane protein and outer membrane protein to open the channel and move the toxin out of the cell. This mechanism uses an energy-dependent, protein-protein interaction that is generated by the transfer of the toxin for an H+ ion by the inner membrane transporter.[7] The fully assembled in vitro and in vivo structures of AcrAB-TolC pump have been solved by cryoEM and cryoET.[8][9]

Function

edit

Although antibiotics are the most clinically important substrates of efflux systems, it is probable that most efflux pumps have other natural physiological functions. Examples include:

  • The E. coli AcrAB efflux system, which has a physiologic role of pumping out bile acids and fatty acids to lower their toxicity.[10]
  • The MFS family Ptr pump in Streptomyces pristinaespiralis appears to be an autoimmunity pump for this organism when it turns on production of pristinamycins I and II.[11]
  • The AcrAB–TolC system in E. coli is suspected to have a role in the transport of the calcium-channel components in the E. coli membrane.[12]
  • The MtrCDE system plays a protective role by providing resistance to faecal lipids in rectal isolates of Neisseria gonorrhoeae.[13]
  • The AcrAB efflux system of Erwinia amylovora is important for this organism's virulence, plant (host) colonization, and resistance to plant toxins.[14]
  • The MexXY component of the MexXY-OprM multidrug efflux system of P. aeruginosa is inducible by antibiotics that _target ribosomes via the PA5471 gene product.[15]
  • Efflux pumps have also been shown to play a role in biofilm formation. However, the substrates for such pumps, and whether changes in their efflux activity affect biofilm formation directly or indirectly, remain to be determined.[16]

The ability of efflux systems to recognize a large number of compounds other than their natural substrates is probably because substrate recognition is based on physicochemical properties, such as hydrophobicity, aromaticity and ionizable character rather than on defined chemical properties, as in classical enzyme-substrate or ligand-receptor recognition. Because most antibiotics are amphiphilic molecules - possessing both hydrophilic and hydrophobic characters - they are easily recognized by many efflux pumps.[citation needed]

Impact on antimicrobial resistance

edit

The impact of efflux mechanisms on antimicrobial resistance is large; this is usually attributed to the following:

  • The genetic elements encoding efflux pumps may be encoded on chromosomes and/or plasmids, thus contributing to both intrinsic (natural) and acquired resistance respectively. As an intrinsic mechanism of resistance, efflux pump genes can survive a hostile environment (for example in the presence of antibiotics) which allows for the selection of mutants that over-express these genes. Being located on transportable genetic elements as plasmids or transposons is also advantageous for the microorganisms as it allows for the easy spread of efflux genes between distant species.[17]
  • Antibiotics can act as inducers and regulators of the expression of some efflux pumps.[15]
  • Expression of several efflux pumps in a given bacterial species may lead to a broad spectrum of resistance when considering the shared substrates of some multi-drug efflux pumps, where one efflux pump may confer resistance to a wide range of antimicrobials.[2]

Eukaryotic

edit

In eukaryotic cells, the existence of efflux pumps has been known since the discovery of P-glycoprotein in 1976 by Juliano and Ling.[18] Efflux pumps are one of the major causes of anticancer drug resistance in eukaryotic cells. They include monocarboxylate transporters (MCTs), multiple drug resistance proteins (MDRs)- also referred as P-glycoprotein, multidrug resistance-associated proteins (MRPs), peptide transporters (PEPTs), and Na+ phosphate transporters (NPTs). These transporters are distributed along particular portions of the renal proximal tubule, intestine, liver, blood–brain barrier, and other portions of the brain.

Inhibitors

edit

Several trials are currently being conducted to develop drugs that can be co-administered with antibiotics to act as inhibitors for the efflux-mediated extrusion of antibiotics. As yet, no efflux inhibitor has been approved for therapeutic use, but some are being used to determine the prevalence of efflux pumps in clinical isolates and in cell biology research. Verapamil, for example, is used to block P-glycoprotein-mediated efflux of DNA-binding fluorophores, thereby facilitating fluorescent cell sorting for DNA content. Various natural products have been shown to inhibit bacterial efflux pumps including the carotenoids capsanthin and capsorubin,[19] the flavonoids rotenone and chrysin,[19] and the alkaloid lysergol.[20] Some nanoparticles, for example zinc oxide, also inhibit bacterial efflux pumps.[21]

See also

edit

References

edit
  1. ^ Sharma A, Gupta VK, Pathania R (February 2019). "Efflux pump inhibitors for bacterial pathogens: From bench to bedside". Indian J Med Res. 149 (2): 129–145. doi:10.4103/ijmr.IJMR_2079_17. PMC 6563736. PMID 31219077.
  2. ^ a b Blanco P, Hernando-Amado S, Reales-Calderon JA, Corona F, Lira F, Alcalde-Rico M, Bernardini A, Sanchez MB, Martinez JL (February 2016). "Bacterial Multidrug Efflux Pumps: Much More Than Antibiotic Resistance Determinants". Microorganisms. 4 (1): 14. doi:10.3390/microorganisms4010014. PMC 5029519. PMID 27681908.
  3. ^ Bay DC, Turner RJ (2016). Small Multidrug Resistance Efflux Pumps. Switzerland: Springer International Publishing. p. 45. ISBN 978-3-319-39658-3.
  4. ^ Sun J, Deng Z, Yan A (October 2014). "Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations". Biochemical and Biophysical Research Communications. 453 (2): 254–67. doi:10.1016/j.bbrc.2014.05.090. PMID 24878531.
  5. ^ a b c d e Delmar JA, Su CC, Yu EW (2014). "Bacterial multidrug efflux transporters". Annual Review of Biophysics. 43: 93–117. doi:10.1146/annurev-biophys-051013-022855. PMC 4769028. PMID 24702006.
  6. ^ Lubelski J, Konings WN, Driessen AJ (September 2007). "Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria". Microbiology and Molecular Biology Reviews. 71 (3): 463–76. doi:10.1128/MMBR.00001-07. PMC 2168643. PMID 17804667.
  7. ^ Ughachukwu P, Unekwe P (July 2012). "Efflux pump-mediated resistance in chemotherapy". Annals of Medical and Health Sciences Research. 2 (2): 191–8. doi:10.4103/2141-9248.105671. PMC 3573517. PMID 23439914.
  8. ^ Wang Z, Fan G, Hryc CF, Blaza JN, Serysheva II, Schmid MF, Chiu W, Luisi BF, Du D (29 March 2017). "An allosteric transport mechanism for the AcrAB-TolC multidrug efflux pump". eLife. 6. doi:10.7554/eLife.24905. PMC 5404916. PMID 28355133.
  9. ^ Shi X, Chen M, Yu Z, Bell JM, Wang H, Forrester I, Villarreal H, Jakana J, Du D, Luisi BF, Ludtke SJ, Wang Z (14 June 2019). "In situ structure and assembly of the multidrug efflux pump AcrAB-TolC". Nature Communications. 10 (1): 2635. Bibcode:2019NatCo..10.2635S. doi:10.1038/s41467-019-10512-6. PMC 6570770. PMID 31201302.
  10. ^ Okusu H, Ma D, Nikaido H (January 1996). "AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants". Journal of Bacteriology. 178 (1): 306–8. doi:10.1128/jb.178.1.306-308.1996. PMC 177656. PMID 8550435.
  11. ^ Vecchione JJ, Alexander B, Sello JK (November 2009). "Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor". Antimicrobial Agents and Chemotherapy. 53 (11): 4673–7. doi:10.1128/AAC.00853-09. PMC 2772354. PMID 19687245.
  12. ^ Du D, Wang Z, James NR, Voss JE, Klimont E, Ohene-Agyei T, Venter H, Chiu W, Luisi BF (May 2014). "Structure of the AcrAB-TolC multidrug efflux pump". Nature. 509 (7501): 512–5. Bibcode:2014Natur.509..512D. doi:10.1038/nature13205. PMC 4361902. PMID 24747401.
  13. ^ Rouquette C, Harmon JB, Shafer WM (August 1999). "Induction of the mtrCDE-encoded efflux pump system of Neisseria gonorrhoeae requires MtrA, an AraC-like protein". Molecular Microbiology. 33 (3): 651–8. doi:10.1046/j.1365-2958.1999.01517.x. PMID 10417654.
  14. ^ Pletzer D, Weingart H (January 2014). "Characterization of AcrD, a resistance-nodulation-cell division-type multidrug efflux pump from the fire blight pathogen Erwinia amylovora". BMC Microbiology. 14: 13. doi:10.1186/1471-2180-14-13. PMC 3915751. PMID 24443882.
  15. ^ a b Morita Y, Sobel ML, Poole K (March 2006). "Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product". Journal of Bacteriology. 188 (5): 1847–55. doi:10.1128/JB.188.5.1847-1855.2006. PMC 1426571. PMID 16484195.
  16. ^ Alav I, Sutton JM, Rahman KM (February 2018). "Role of bacterial efflux pumps in biofilm formation". Journal of Antimicrobial Chemotherapy. 73 (8): 2003–2020. doi:10.1093/jac/dky042. PMID 29506149.
  17. ^ Li XZ, Plésiat P, Nikaido H (April 2015). "The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria". Clinical Microbiology Reviews. 28 (2): 337–418. doi:10.1128/CMR.00117-14. PMC 4402952. PMID 25788514.
  18. ^ Juliano RL, Ling V (November 1976). "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants". Biochimica et Biophysica Acta (BBA) - Biomembranes. 455 (1): 152–62. doi:10.1016/0005-2736(76)90160-7. PMID 990323.
  19. ^ a b Molnár J, Engi H, Hohmann J, Molnár P, Deli J, Wesolowska O, Michalak K, Wang Q (2010). "Reversal of multidrug resistance by natural substances from plants". Current Topics in Medicinal Chemistry. 10 (17): 1757–68. doi:10.2174/156802610792928103. PMID 20645919.
  20. ^ Cushnie TP, Cushnie B, Lamb AJ (November 2014). "Alkaloids: an overview of their antibacterial, antibiotic-enhancing and antivirulence activities" (PDF). International Journal of Antimicrobial Agents. 44 (5): 377–86. doi:10.1016/j.ijantimicag.2014.06.001. PMID 25130096. S2CID 205171789.
  21. ^ Banoee M, Seif S, Nazari ZE, Jafari-Fesharaki P, Shahverdi HR, Moballegh A, Moghaddam KM, Shahverdi AR (May 2010). "ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against Staphylococcus aureus and Escherichia coli" (PDF). Journal of Biomedical Materials Research Part B: Applied Biomaterials. 93 (2): 557–61. doi:10.1002/jbm.b.31615. PMID 20225250.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Efflux_pump&oldid=1232762076"
  NODES
admin 1
INTERN 2
Note 1